Corporate strategies and tactics for more effective drug development.
November 18, 2009
By:Andrew Sheivachman
Dubbed as the 'female Viagra,' Boehringer Ingelheim's filbanserin represents an unprecedented step forward in treating female sexual dysfunction.
 |
November 18, 2009
By:Emmanuel Le Poul
Allosteric modulators are an emerging class of orally available small molecule drugs that may have multiple advantages compared to traditional drugs.
|
 | November 4, 2009
By:Bassil Dahiyat
As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics.
|
October 14, 2009
By:Jerome Wilson, Martin Nemansky
Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development.
|
 | October 2, 2009
By:Gen Li
How proper site activation and site enrollment can help you get the most from clinical trials.
|
July 22, 2009
By:Chris McKenna
The process of research and development of new drugs has become phenomenally expensive. Can Lean Six Sigma revitalize the innovation process for pharmaceutical companies?
|
July 22, 2009
By:Sarah Houlton
Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.
|
 | July 1, 2009
Capitalize on the new age in healthcare with "disruptive innovation."
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings Tuesday, December 15 @ 11:00 a.m. ET
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?